Fig. 4. Sensitization of myeloid cancer cells to NL101-induced cytotoxicity by rapamycin. (a) The 3-‍(4,5-dimethylthiazol-2-yl)‍-2,5-diphenyltetrazolium bromide (MTT) assays of phosphatase and tensin homologous (PTEN) knockout (PTEN-KO) cell lines exposed to NL101 and/or rapamycin for 48 h. (b) MTT assays of primary acute myeloid leukemia (AML) sample cells exposed to NL101 and/or rapamycin for 24 h. Data are expressed as mean±standard deviation (SD) (n=3). ^* P<0.05, ^** P<0.01, ^*** P<0.001; WT: wide type; Rapa: rapamycin.